chevrons

Back to Previous Page

Company Quarterly Earnings Update – DHG VN – 2018 Q3

Summary of the 9M 2018 results of Hau Giang Pharmaceutical JSC (DHG VN) 

9M/2018 results: highlights
  • Net revenue was VND 2,669 bn, -1.5% y/y. Own product revenue (83% of total revenue) grew by 6% y/y, while the remainder of DHG’s revenue declined by 20% y/y because of the dropout of trading medicine revenue. DHG removed the trading medicine business line in order to be qualified for the foreign ownership limit (FOL) lifting.
  • Profit before tax amounted to VND 512 bn, +3.2% y/y, growing faster than revenue thanks to improved efficiency and thus lower operating expenses. The bottom line was however down by 9.9% y/y as the company paid most  of its 2017 taxes in Q4 due to last year’s tax dispute. This year, tax expenses were distributed more evenly among the quarters.
  • DHG’s financial position remained solid with a large amount of liquid assets (cash and deposits made up 37.6% of total assets) and a low leverage (D/E and D/A of 0.21x and of 0.15x respectively).
Other developments
  • The FOL was fully lifted from 3 Jul 2018. Thereafter, Taisho Pharmaceutical Co., Ltd. increased its stake to 34.3% after making a tender offer for a 7.0% stake at a price of VND120,000/share; afterwards, Taisho purchased an additional 2.3% stake through the open market.
Outlook
  • DHG’s prospects remain bright thanks to strong demand for reasonably priced generic drugs (IQVIA estimates a CAGR of 9% during 2017-2021). What is more, the recent launch of some skincare products in cooperation with Taisho’s partners have opened the cosmetics and the supplements market. However, cosmetics currently account for less than 10% of DHG’s revenue.
  • The 2018 and the 2019 bottom lines are estimated to reach VND 674 bn (+4.8% y/y) and 741 bn (+9.9% y/y) respectively.
Recommendation

Company ratings and target prices are accessible for clients only.

If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.

Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.

 

Featured image credit: ndh.vn

 

Related News & Insights
Find out more navigation_button
news

Summary of Q1 2026 results and outlook of Quang Ngai Sugar JSC (QNS VN) Net revenue increased 21.8% y/y to VND 2,763bn, partly reflecting a low base effect as plant-based beverage revenue rebounded 21.5% y/y from last year’s tax-compliance disruptions in General Trade channel, while also benefiting from a more premium product mix. The sugar […]

Read Newsarrow
news

Summary of Q1 2026 results and outlook of Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD VN) Net revenue rose 1.6% y/y to VND448bn. Growth was led by kidney dialysis products (+11.8% y/y), minerals, vitamins & supplements (+29.4% y/y), and psychiatric & neurological disorder therapies (+20.5% y/y). Oncology products (+1.5% y/y) and antibiotics (-15.2% y/y) […]

Read Newsarrow
news

Summary of Q1 2026 results and outlook of Nam Long Investment (NLG VN) The real estate market continued to record an increase in new supply, supported by the ongoing easing of legal procedures. However, supply-demand imbalances persist in major cities, where new launches remain concentrated in the high-end and luxury segments. On the demand side, […]

Read Newsarrow
Find out more navigation_button